Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Maternus-Kliniken AGHAM:MAK -0.55%41 EV-to-EBITDA is 48.48 as of Aug. 09, 2026, which is 173% above its 10-year median of 17.75. GuruFocus rates HAM:MAK with a GF Score™ of 41/100 and a GF Value™ of €1.79. The stock has 4 warning signs investors should review. Among 512 Healthcare Providers & Services companies, Maternus-Kliniken AG ranks worse than 91.41% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Maternus-Kliniken AG's enterprise value is €197.6 Mil.
Maternus-Kliniken AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €4.1 Mil. Therefore, Maternus-Kliniken AG's EV-to-EBITDA for today is 48.48.
The historical rank and industry rank for Maternus-Kliniken AG's EV-to-EBITDA or its related term are showing as below:
HAM:MAK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.09 Med: 17.75 Max: 58.68
Current: 48.48
During the past 13 years, the highest EV-to-EBITDA of Maternus-Kliniken AG was 58.68. The lowest was 8.09. And the median was 17.75.
HAM:MAK's EV-to-EBITDA is ranked worse than 91.41% of 512
companies
in the Healthcare Providers & Services industry
Industry Median: 10.965
vs HAM:MAK: 48.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Maternus-Kliniken AG (HAM:MAK) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Maternus-Kliniken AG's PE Ratio (TTM) for today is calculated as:
Maternus-Kliniken AG's share price for today is €0.905.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Maternus-Kliniken AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.660.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Maternus-Kliniken AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Maternus-Kliniken AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maternus-Kliniken AG EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Maternus-Kliniken AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Maternus-Kliniken AG's EV-to-EBITDA falls into.
Maternus-Kliniken AG's current Enterprise Value is €197.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Maternus-Kliniken AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €4.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maternus-Kliniken AG (HAM:MAK) has a EV-to-EBITDA of 48.48 as of Aug. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Maternus-Kliniken AG. This is 173% above median its historical median of 17.75. Over the past decade, Maternus-Kliniken AG's EV-to-EBITDA has ranged from 8.09 to 58.68. According to the industry distribution chart, Maternus-Kliniken AG ranks #468 out of 512 companies in the Healthcare Providers & Services industry, placing it in the top 91.4%.
Is Maternus-Kliniken AG's EV-to-EBITDA too high?
Maternus-Kliniken AG's current EV-to-EBITDA of 48.48 is 173% above median its 10-year median of 17.75. Over the past 10 years, this metric has ranged from a low of 8.09 to a high of 58.68. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.97. Maternus-Kliniken AG's value of 48.48 is 342.1% above this industry median. Based on the distribution chart, Maternus-Kliniken AG ranks #468 out of 512 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Maternus-Kliniken AG has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Maternus-Kliniken AG's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Maternus-Kliniken AG ranks #468 out of 512 companies for EV-to-EBITDA. This places Maternus-Kliniken AG in the lower half of its industry. The industry median EV-to-EBITDA is 10.97. Maternus-Kliniken AG's value of 48.48 is 342.1% above this benchmark. Historically, Maternus-Kliniken AG's own EV-to-EBITDA has ranged from 8.09 to 58.68 over the past decade. While the company's 10-year median is 17.75 vs. the industry median of 10.97, Maternus-Kliniken AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.97, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maternus-Kliniken AG's current EV-to-EBITDA of 48.48 is 342.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Maternus-Kliniken AG. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maternus-Kliniken AG's current EV-to-EBITDA is 48.48, which is 173% above median its own 10-year median of 17.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maternus-Kliniken AG stock overvalued right now?
Maternus-Kliniken AG (HAM:MAK) has a current EV-to-EBITDA of 48.48. The stock's GF Value™ is €1.79, compared to a current price of €0.91 — trading 49.4% below its estimated fair value. The current EV-to-EBITDA is 48.48, which is 173% above median its 10-year median of 17.75 and 342.1% above the Healthcare Providers & Services industry median of 10.97. Maternus-Kliniken AG's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Maternus-Kliniken AG (HAM:MAK), the current EV-to-EBITDA is 48.48 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maternus-Kliniken AG (HAM:MAK) Overvalued in 2026?
Based on GuruFocus' analysis, Maternus-Kliniken AG stock appears to be undervalued.
The current stock price of €0.91 is trading 49.4% below its estimated GF Value™ of €1.79.
Key valuation signals for HAM:MAK:
EV-to-EBITDA: 48.48 (173% above median its 10-year median of 17.75)
GF Value™: €1.79 vs. price of €0.91 (49.4% below fair value)
Industry Position: 342.1% above the Healthcare Providers & Services median (#468 of 512)
No single metric tells the full story. See the HAM:MAK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:MAK has been successfully added to your 
